MA45712A - Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations - Google Patents

Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations

Info

Publication number
MA45712A
MA45712A MA045712A MA45712A MA45712A MA 45712 A MA45712 A MA 45712A MA 045712 A MA045712 A MA 045712A MA 45712 A MA45712 A MA 45712A MA 45712 A MA45712 A MA 45712A
Authority
MA
Morocco
Prior art keywords
gprc5d
bind
binding molecules
bispecific antigen
antibodies
Prior art date
Application number
MA045712A
Other languages
English (en)
Other versions
MA45712B1 (fr
Inventor
Ricardo Attar
Diana Chin
Suzanne Edavettal
Francois Gaudet
Yingzhe Li
Leopoldo Luistro
Nathan Majewski
Mark Mendonca
Kondandaram Pillarisetti
Alexey Teplyakov
Mark Tornetta
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA45712A publication Critical patent/MA45712A/fr
Publication of MA45712B1 publication Critical patent/MA45712B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA45712A 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations MA45712B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364811P 2016-07-20 2016-07-20
PCT/US2017/042982 WO2018017786A2 (fr) 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
EP17745951.8A EP3487882B1 (fr) 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA45712A true MA45712A (fr) 2019-05-29
MA45712B1 MA45712B1 (fr) 2025-09-30

Family

ID=60992891

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45712A MA45712B1 (fr) 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations

Country Status (41)

Country Link
US (4) US10562968B2 (fr)
EP (2) EP4643953A3 (fr)
JP (3) JP7292200B2 (fr)
KR (3) KR20250073578A (fr)
CN (2) CN116333133A (fr)
AR (4) AR109499A1 (fr)
AU (2) AU2017299673B2 (fr)
CA (1) CA3031472A1 (fr)
CL (4) CL2019000146A1 (fr)
CO (1) CO2019001114A2 (fr)
CR (1) CR20190025A (fr)
DK (1) DK3487882T3 (fr)
EA (1) EA201990346A1 (fr)
EC (1) ECSP19012075A (fr)
ES (1) ES3042078T3 (fr)
FI (2) FI3487882T3 (fr)
FR (1) FR26C1002I1 (fr)
HR (1) HRP20251181T1 (fr)
HU (1) HUE073077T2 (fr)
IL (2) IL264334B2 (fr)
IN (1) IN201917002488A (fr)
LT (2) LT3487882T (fr)
MA (1) MA45712B1 (fr)
MD (1) MD3487882T2 (fr)
MX (3) MX2019000825A (fr)
NI (1) NI201900005A (fr)
NL (1) NL301360I2 (fr)
NO (1) NO2026001I1 (fr)
NZ (2) NZ790480A (fr)
PE (2) PE20240884A1 (fr)
PH (1) PH12019500152A1 (fr)
PL (1) PL3487882T3 (fr)
PT (1) PT3487882T (fr)
RS (1) RS67235B1 (fr)
SG (1) SG11201900468YA (fr)
SI (1) SI3487882T1 (fr)
SM (1) SMT202500356T1 (fr)
TW (1) TWI781108B (fr)
UY (5) UY40672A (fr)
WO (1) WO2018017786A2 (fr)
ZA (1) ZA201901066B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CA3011942A1 (fr) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Constructions d'anticorps impliquant des cellules t bispecifiques psma et cd3
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
WO2018035710A1 (fr) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
RU2019128134A (ru) * 2017-02-07 2021-03-09 Дайити Санкио Компани, Лимитед Антитело против gprc5d и молекула, содержащая антитело
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
CN111116753A (zh) * 2018-10-30 2020-05-08 上海泰因生物技术有限公司 一种双特异性抗体的制备方法
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
JP7621948B2 (ja) * 2018-12-04 2025-01-27 ノバルティス アーゲー Ｃｄ３に対する結合分子及びその使用
MX2021007320A (es) 2018-12-21 2021-07-07 Hoffmann La Roche Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
PH12021551676A1 (en) * 2019-01-18 2022-03-07 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
CN119192386A (zh) * 2019-07-31 2024-12-27 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
JP2022543551A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
CN115335399A (zh) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
KR20220160598A (ko) 2020-03-30 2022-12-06 고쿠리츠다이가쿠호진 미에다이가쿠 이중 특이적 항체
JP7844430B2 (ja) * 2020-07-17 2026-04-13 ヤンセン バイオテツク，インコーポレーテツド 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体
EP4213945A1 (fr) * 2020-09-16 2023-07-26 Janssen Biotech, Inc. Méthodes de traitement d'un myélome multiple
SMT202600020T1 (it) * 2021-01-05 2026-03-09 Lanova Medicines Development Co Ltd Anticorpi monoclonali anti-gprc5d e usi di essi
WO2022148370A1 (fr) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anticorps monoclonaux anti-gprc5d et leurs utilisations
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
IL305144A (en) 2021-02-16 2023-10-01 Janssen Pharmaceutica Nv Trispecific antibodies targeting BCMA, GPRC5D and CD3
JP2024510098A (ja) * 2021-02-19 2024-03-06 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用
CA3214594A1 (fr) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Anticorps trispecifique ciblant cd79b, cd20 et cd3
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
WO2022247804A1 (fr) * 2021-05-23 2022-12-01 上海祥耀生物科技有限责任公司 Anticorps anti-gprc5d, son procédé de préparation et son utilisation
JP2024534847A (ja) * 2021-08-30 2024-09-26 オリセル セラピューティクス カンパニー リミテッド 抗ｇｐｒｃ５ｄ抗原結合タンパク質とその使用
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
TW202334222A (zh) * 2021-11-05 2023-09-01 大陸商正大天晴藥業集團股份有限公司 結合gprc5d的抗體及其用途
WO2023173272A1 (fr) * 2022-03-15 2023-09-21 上海驯鹿生物技术有限公司 Récepteur antigénique chimérique (car) entièrement humanisé ciblant gprc5d et son utilisation
WO2023115347A1 (fr) * 2021-12-21 2023-06-29 上海驯鹿生物技术有限公司 Anticorps entièrement humain ciblant gprc5d
AU2022418639A1 (en) 2021-12-21 2024-08-01 Shanghai Iaso Biotechnology Co., Ltd. Fully human antibody targeting gprc5d and chimeric antigen receptor (car) and use thereof
WO2023125728A1 (fr) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 Anticorps anti-gprc5d et son utilisation
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
US20250145705A1 (en) * 2021-12-31 2025-05-08 Shandong Simcere Biopharmaceutical Co., Ltd. Gprc5d antibody and application thereof
JP2025504795A (ja) * 2022-01-10 2025-02-19 ナンチン リーズ バイオラブス カンパニー，リミティド 抗体及びその用途
US20250121064A1 (en) * 2022-01-29 2025-04-17 Carsgen Life Sciences Co., Ltd Gprc5d antibody and use thereof
CN118660910A (zh) * 2022-03-14 2024-09-17 江苏恒瑞医药股份有限公司 特异性结合gprc5d和cd3的抗原结合分子及其医药用途
CA3247475A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
JP2025523359A (ja) * 2022-05-27 2025-07-23 アンテンジーン バイオロジクス リミテッド 新規抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄおよびｃｄ３に結合する二特異性抗原結合分子、ならびにその使用
KR20250021313A (ko) * 2022-06-06 2025-02-12 산둥심시어 바이오파마슈티칼 씨오., 엘티디. Bcma, gprc5d 및 t 세포를 표적으로 하는 다중특이적 항체 및 그 응용
JP2025521745A (ja) * 2022-06-30 2025-07-10 康諾亜生物医薬科技（成都）有限公司 新規多重特異的腫瘍阻害剤の開発および使用
CN119698434A (zh) * 2022-07-21 2025-03-25 山东先声生物制药有限公司 抗gprc5d纳米抗体及其应用
CN120051298A (zh) 2022-08-05 2025-05-27 朱诺治疗学股份有限公司 Gprc5d和bcma特异性嵌合抗原受体
CN116003598B (zh) 2022-08-30 2024-04-26 苏州缔码生物科技有限公司 靶向人gprc5d的重组人源化单克隆抗体及其应用
CN120129696A (zh) 2022-09-01 2025-06-10 乔治亚大学研究基金公司 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法
KR20250057914A (ko) * 2022-09-09 2025-04-29 베이징 맵웍스 바이오테크 컴퍼니 리미티드 다중-특이적 항체 결합 bcma, gprc5d 및 cd3 및 이의 용도
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
WO2024102954A1 (fr) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Système d'écrêtage induit par activation (aics)
KR20250123204A (ko) * 2022-12-22 2025-08-14 얀센 파마슈티카 엔브이 항체-폴리뉴클레오티드 접합체의 제조 방법
TW202434644A (zh) 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 三特異性抗原結合分子及其應用
JP2026506095A (ja) 2023-02-17 2026-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
US20240392027A1 (en) 2023-02-28 2024-11-28 Janssen Biotech Inc. Compositions comprising a bispecific gprc5d/cd3 antibody
WO2024192704A1 (fr) * 2023-03-22 2024-09-26 Biofront Therapeutics (Beijing) Co., Ltd. Nanocorps se liant à gprc5d et leurs utilisations
EP4703384A1 (fr) * 2023-04-28 2026-03-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anticorps bispécifique ciblant un récepteur couplé à une protéine g
TW202446793A (zh) * 2023-05-16 2024-12-01 大陸商上海齊魯製藥研究中心有限公司 雙特異性抗原結合分子及其應用
KR20260020402A (ko) 2023-06-01 2026-02-11 얀센 바이오테크 인코포레이티드 다발성 골수종의 치료 방법
CN121335930A (zh) 2023-06-06 2026-01-13 信达生物制药(苏州)有限公司 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
KR20260021753A (ko) * 2023-06-09 2026-02-13 안텐진 바이올로직스 리미티드 Cd3 및 다른 표적을 표적화하는 신규 항체 및 이의 용도
CN121311505A (zh) * 2023-06-28 2026-01-09 浙江博锐生物制药有限公司 抗gprc5d抗体及其医药用途
WO2025019733A2 (fr) * 2023-07-20 2025-01-23 Janssen Biotech, Inc. Procédés de traitement du myélome multiple
WO2025056013A1 (fr) * 2023-09-13 2025-03-20 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un anticorps bispécifique se liant de manière spécifique à gprc5d et cd3
WO2025059362A1 (fr) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025076472A1 (fr) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
WO2025094085A1 (fr) 2023-10-31 2025-05-08 Janssen Biotech, Inc. Schémas combinés pour le traitement du myélome multiple
WO2025122929A1 (fr) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. Anticorps de gprc5d à fonction effectrice améliorée et leurs utilisations
WO2025134050A1 (fr) 2023-12-21 2025-06-26 Janssen Biotech, Inc Anticorps trispécifique ciblant bcma, gprc5d et cd3 pour le traitement du myélome multiple
WO2025134049A1 (fr) 2023-12-21 2025-06-26 Janssen Biotech, Inc Anticorps trispécifique ciblant bcma, gprc5d et cd3 pour le traitement de l'amylose al
WO2025147545A1 (fr) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et procédés et utilisations associés
CN117843788B (zh) * 2024-01-09 2025-02-11 四川大学 一种抗gprc5d的抗体及其多特异性抗体和相关应用
CN118108846B (zh) * 2024-02-04 2024-11-26 四川大学华西医院 靶向GPRC5D同种异体CAR-γδT细胞的制备及应用
WO2025194478A1 (fr) * 2024-03-22 2025-09-25 Biofront Ltd Anticorps se liant à cd3 et gprc5d et leurs utilisations
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025259877A1 (fr) * 2024-06-12 2025-12-18 Evolveimmune Therapeutics, Inc. Molécules de fusion d'anticorps bispécifique ciblant gprc5d et cd3 et leurs procédés d'utilisation
WO2026001924A1 (fr) * 2024-06-24 2026-01-02 南京蓬勃生物科技有限公司 Anticorps se liant à gprc5d et son utilisation
WO2026001931A1 (fr) * 2024-06-24 2026-01-02 南京蓬勃生物科技有限公司 Molécule se liant à gprc5d et son utilisation
WO2026015729A1 (fr) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques gprc5d x cd28 et leurs procédés d'utilisation
US12545726B1 (en) 2025-07-22 2026-02-10 Integral Molecular, Inc. Compositions and methods related to GPRC5D binding agents and variants thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1468694A1 (fr) * 2001-12-27 2004-10-20 Sumitomo Pharmaceuticals Company, Limited Medicaments contre l'anorexie ou des affections liees au mode de vie et procede de recherche systematique de ces medicaments
WO2005086568A2 (fr) * 2004-01-26 2005-09-22 Morphosys Ag Anticorps anti-icam 1 humains et utilisations de ceux-ci
CA2577082A1 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
NZ589036A (en) * 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP4180458A1 (fr) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Anticorps bispécifique à chaîne unique psma x cd3 particulière d'une espèce à l'autre
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
CA2738568C (fr) 2008-10-01 2024-02-20 Micromet Ag Anticorps monocatenaire bispecifique a domaine unique, specifique d'especes croisees
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
WO2010093627A2 (fr) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
WO2012158818A2 (fr) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
FR2994803B1 (fr) 2012-08-30 2016-02-26 Oreal Modulation de la forme des fibres keratiniques
WO2014131712A1 (fr) 2013-02-26 2014-09-04 Roche Glycart Ag Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
DK3189081T3 (da) * 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
KR102602417B1 (ko) * 2014-12-05 2023-11-16 메모리얼 슬로안 케터링 캔서 센터 G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
WO2017031104A1 (fr) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
US20170121420A1 (en) 2015-11-02 2017-05-04 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
RU2019128134A (ru) 2017-02-07 2021-03-09 Дайити Санкио Компани, Лимитед Антитело против gprc5d и молекула, содержащая антитело
WO2019094626A1 (fr) 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Compositions d'anticorps bispécifiques et méthodes associées pour des radioimunothérapies préciblées améliorées
EP4213945A1 (fr) 2020-09-16 2023-07-26 Janssen Biotech, Inc. Méthodes de traitement d'un myélome multiple
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物

Also Published As

Publication number Publication date
JP2019527061A (ja) 2019-09-26
AR109499A1 (es) 2018-12-19
UY40770A (es) 2024-06-28
KR102811945B1 (ko) 2025-05-23
LT3487882T (lt) 2025-10-10
EP4643953A2 (fr) 2025-11-05
SI3487882T1 (sl) 2025-11-28
US20240343796A1 (en) 2024-10-17
DK3487882T3 (da) 2025-09-22
EA201990346A1 (ru) 2019-06-28
US11685777B2 (en) 2023-06-27
PH12019500152A1 (en) 2019-10-14
CN116333133A (zh) 2023-06-27
PE20240884A1 (es) 2024-04-24
MA45712B1 (fr) 2025-09-30
HRP20251181T1 (hr) 2025-12-05
FIC20265003I1 (fi) 2026-01-12
US20180037651A1 (en) 2018-02-08
IL264334A (en) 2019-02-28
ES3042078T3 (en) 2025-11-18
PE20190392A1 (es) 2019-03-13
IL264334B2 (en) 2024-05-01
EP4643953A3 (fr) 2026-04-01
KR20190028534A (ko) 2019-03-18
ZA201901066B (en) 2020-10-28
NI201900005A (es) 2019-05-10
UY37340A (es) 2018-01-31
HUE073077T2 (hu) 2025-12-28
FI3487882T3 (fi) 2025-09-25
MD3487882T2 (ro) 2026-03-31
BR112019001055A2 (pt) 2019-10-01
KR102572091B1 (ko) 2023-08-31
KR20250073578A (ko) 2025-05-27
UY40768A (es) 2024-06-28
AR132097A2 (es) 2025-05-28
LTPA2026501I1 (fr) 2026-01-26
MX2023006449A (es) 2023-06-15
CA3031472A1 (fr) 2018-01-25
CL2024000444A1 (es) 2024-08-23
MX2019000825A (es) 2019-09-04
NL301360I2 (nl) 2026-02-10
CL2019000146A1 (es) 2019-04-26
AR133827A2 (es) 2025-11-05
PL3487882T3 (pl) 2025-11-17
UY40672A (es) 2024-04-30
AU2024205021A1 (en) 2024-08-15
PT3487882T (pt) 2025-10-13
WO2018017786A2 (fr) 2018-01-25
SG11201900468YA (en) 2019-02-27
CL2024001016A1 (es) 2024-10-04
EP3487882A2 (fr) 2019-05-29
CN109715667A (zh) 2019-05-03
EP3487882B1 (fr) 2025-07-16
ECSP19012075A (es) 2019-02-28
CN109715667B (zh) 2022-12-30
JP7469432B2 (ja) 2024-04-16
TW201809005A (zh) 2018-03-16
NO2026001I1 (no) 2026-01-12
RS67235B1 (sr) 2025-10-31
CO2019001114A2 (es) 2019-02-19
AU2017299673B2 (en) 2024-08-01
JP2024054176A (ja) 2024-04-16
IN201917002488A (fr) 2019-04-26
JP7292200B2 (ja) 2023-06-16
KR20230128409A (ko) 2023-09-04
AU2017299673A1 (en) 2019-02-07
JP2023011774A (ja) 2023-01-24
CL2024001015A1 (es) 2024-10-04
WO2018017786A3 (fr) 2018-03-01
US20230084967A1 (en) 2023-03-16
US11884722B2 (en) 2024-01-30
IL264334B1 (en) 2024-01-01
US10562968B2 (en) 2020-02-18
AR133826A2 (es) 2025-11-05
NZ750152A (en) 2025-12-19
MX2024001615A (es) 2024-02-28
US20230227548A1 (en) 2023-07-20
FR26C1002I1 (fr) 2026-03-06
UY40769A (es) 2024-06-28
CR20190025A (es) 2019-03-14
TWI781108B (zh) 2022-10-21
SMT202500356T1 (it) 2025-11-10
NZ790480A (en) 2025-12-19
IL298277A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
FR26C1002I1 (fr) Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
MA46417A (fr) Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
FR23C1012I2 (fr) Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
FR25C1029I2 (fr) Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
MA43164A (fr) Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
MA52771A (fr) Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations
EP3891187A4 (fr) Anticorps bispécifiques anti-pd-l1/anti-4-1bb et leurs utilisations
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
EP3411071A4 (fr) Nouveaux anticorps monoclonaux anti-cd 47 et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
MA52022A (fr) Anticorps qui se lient à cd39 et leurs utilisations
MA50900A (fr) Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
EP3891181A4 (fr) Molécules de liaison à cd3 et leurs utilisations
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA49565A (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
EP3411069A4 (fr) Anticorps humanisés anti-cd3, conjugués et leurs utilisations
EP3897719A4 (fr) Anticorps bispécifiques clivables par la protéase et utilisations associées
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
EP3426686A4 (fr) Anticorps anti-pacap humanisés et leurs utilisations
EP3389699A4 (fr) Anticorps monoclonaux chimériques et humanisés anti-ctla4 humaine, et leurs utilisations
EP3710484A4 (fr) Anticorps de liaison à ctla-4 et leurs utilisations
EP3773716A4 (fr) Anticorps monoclonaux qui se lient à ssea4 et leurs utilisations